Pharmaceutical

CPHI Europe: Overcoming the unique challenges with high-concentration mAbs

High-concentration monoclonal antibodies (mAbs) are gaining prominence given the compliance and cost advantages.

Oct 12, 2024 - 04:00
CPHI Europe: Overcoming the unique challenges with high-concentration mAbs
High-concentration monoclonal antibodies (mAbs) are gaining prominence given the compliance and cost advantages.
Read the original article

Tags:

Previous Article

CPHI Europe: Targeting supply chain bottlenecks key for cell and gene therapies

Next Article

The medical device sector’s surging regulatory burden: how are suppliers coping?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Regeneron and Sanofi’s Dupixent bags fifth drug label in Japan

Regeneron and Sanofi’s Dupixent bags fifth drug label i...

Feb 16, 2024

CD70 CAR-T by UTC Therapeutics for Relapsed Chronic Lym...

Aug 10, 2023

BioAegis scores $20m BARDA contract to develop ARDS therapy

BioAegis scores $20m BARDA contract to develop ARDS the...

Oct 17, 2023